These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 24243574)

  • 21. Response to Chauhan et Al.: interstitial pressure and vascular collapse in pancreas cancer-fluids and solids, measurement and meaning.
    DelGiorno KE; Carlson MA; Osgood R; Provenzano PP; Brockenbough JS; Thompson CB; Shepard HM; Frost GI; Potter JD; Hingorani SR
    Cancer Cell; 2014 Jul; 26(1):16-7. PubMed ID: 25026210
    [No Abstract]   [Full Text] [Related]  

  • 22. Pancreatic cancer: standing on the shoulders of mice, making an iMPACT on pancreatic cancer.
    Villanueva MT
    Nat Rev Clin Oncol; 2013 Dec; 10(12):665. PubMed ID: 24189469
    [No Abstract]   [Full Text] [Related]  

  • 23. Gemcitabine-resistant pancreatic cancer: a second-line option.
    Oettle H; Lehmann T
    Lancet; 2016 Feb; 387(10018):507-508. PubMed ID: 26616909
    [No Abstract]   [Full Text] [Related]  

  • 24. Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer.
    Beg MS; Huang X; Silvers MA; Gerber DE; Bolluyt J; Sarode V; Fattah F; Deberardinis RJ; Merritt ME; Xie XJ; Leff R; Laheru D; Boothman DA
    J Surg Oncol; 2017 Jul; 116(1):83-88. PubMed ID: 28346693
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemotherapy: NAPOLI-1: winning scoop for metastatic pancreatic cancer.
    Hutchinson L
    Nat Rev Clin Oncol; 2016 Jan; 13(1):2-3. PubMed ID: 26667974
    [No Abstract]   [Full Text] [Related]  

  • 26. [Novel Palliative Chemotherapy in Patients with Metastatic Pancreatic Cancer: PEGPH20].
    Kim DU
    Korean J Gastroenterol; 2018 Apr; 71(4):244-245. PubMed ID: 29684975
    [No Abstract]   [Full Text] [Related]  

  • 27. Nanoliposomal irinotecan in metastatic pancreatic cancer.
    Milosevic I; Drysdale H; Goldacre B;
    Lancet; 2016 May; 387(10032):1997. PubMed ID: 27203772
    [No Abstract]   [Full Text] [Related]  

  • 28. Clinical trials: New drug for pancreatic cancer highlights the dual effect of regulatory approvals.
    Bates SE; Fojo T
    Nat Rev Clin Oncol; 2016 Apr; 13(4):205-6. PubMed ID: 26902963
    [No Abstract]   [Full Text] [Related]  

  • 29. Nanoliposomal irinotecan in metastatic pancreatic cancer - Authors' reply.
    Chen LT; Wang-Gillam A; Von Hoff DD; Bayever E; Belanger B
    Lancet; 2016 May; 387(10032):1997. PubMed ID: 27203770
    [No Abstract]   [Full Text] [Related]  

  • 30. Therapeutics: Disrupting a survival signal.
    McCarthy N
    Nat Rev Cancer; 2013 Sep; 13(9):608-9. PubMed ID: 23903094
    [No Abstract]   [Full Text] [Related]  

  • 31. Predicting a response to FOLFIRINOX in pancreatic cancer.
    Nipp RD; Ryan DP
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 26025325
    [No Abstract]   [Full Text] [Related]  

  • 32. Chemotherapy of pancreatic cancer in patients with poor performance.
    Schulz D; Algül H
    Chin Clin Oncol; 2019 Oct; 8(S1):S22. PubMed ID: 31500430
    [No Abstract]   [Full Text] [Related]  

  • 33. Is There Efficacy Beyond Cytotoxic Chemotherapy for Pancreatic Cancer?
    Kalyan A; Benson AB
    J Oncol Pract; 2016 Sep; 12(9):806-7. PubMed ID: 27621333
    [No Abstract]   [Full Text] [Related]  

  • 34. Striving to Move Beyond Chemotherapy in Advanced Pancreatic Cancer.
    Ko AH
    J Oncol Pract; 2016 Sep; 12(9):808-10. PubMed ID: 27621334
    [No Abstract]   [Full Text] [Related]  

  • 35. Drug interactions: the importance of looking inside cancer cells.
    Clark JW
    Cancer Discov; 2012 Mar; 2(3):208-10. PubMed ID: 22585991
    [TBL] [Abstract][Full Text] [Related]  

  • 36. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer.
    Frese KK; Neesse A; Cook N; Bapiro TE; Lolkema MP; Jodrell DI; Tuveson DA
    Cancer Discov; 2012 Mar; 2(3):260-269. PubMed ID: 22585996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models.
    Awasthi N; Scire E; Monahan S; Grojean M; Zhang E; Schwarz MA; Schwarz RE
    Oncotarget; 2016 Jul; 7(30):46988-47001. PubMed ID: 27127884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nab-paclitaxel for metastatic pancreatic cancer: clinical outcomes and potential mechanisms of action.
    Al-Batran SE; Geissler M; Seufferlein T; Oettle H
    Oncol Res Treat; 2014; 37(3):128-34. PubMed ID: 24685917
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [nab-Paclitaxel as new therapeutic option for pancreatic cancer].
    Michl P
    Z Gastroenterol; 2013 Nov; 51(11):1329-30. PubMed ID: 24243574
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.